Drug Trial Radar · NCT06984627
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Actual
Start
Sep 2, 2025
Primary completion
Feb 11, 2027
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older. Study details include: * Screening period (up to 4 weeks). * Treatment period (up to 16 weeks). * Follow-up period (4 weeks). The number of visits will be up to 13.
Conditions
- Graves' Disease
Interventions
Rilzabrutinib dose 1Drug
Pharmaceutical form:Tablet-Route of administration:Oral
Rilzabrutinib dose 2Drug
Pharmaceutical form:Tablet-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in FT4 levelsTime frame: At Week16
Locations
24 sites in 9 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320003
Córdoba, Argentina
Investigational Site Number : 1240003
Calgary, Alberta, Canada
Investigational Site Number : 1240002
Surrey, British Columbia, Canada
Investigational Site Number : 1240001
Sherbrooke, Quebec, Canada
Investigational Site Number : 1520001
Concepción, Biobio, Chile
Investigational Site Number : 1520002
Iquique, Tarapacá, Chile
Investigational Site Number : 2760002
Essen, Germany
Investigational Site Number : 2760001
Frankfurt, Germany
Investigational Site Number : 3000002
Athens, Greece
Investigational Site Number : 3000001
Athens, Greece
Investigational Site Number : 3000003
Larissa, Greece
Investigational Site Number : 3480001
Pécs, Hungary
Investigational Site Number : 3800005
Merano, Italy
Investigational Site Number : 3800003
Palermo, Italy
Investigational Site Number : 3800002
Pisa, Italy
Investigational Site Number : 3800001
Milan, Milano, Italy
Investigational Site Number : 3800004
Milan, Milano, Italy
Investigational Site Number : 7240002
Barcelona, Catalunya [Cataluña], Spain
Investigational Site Number : 7240001
Pamplona, Navarre, Spain
Investigational Site Number : 7240004
Seville, Sevilla, Spain
Investigational Site Number : 8260003
Milton Keynes, Buckinghamshire, United Kingdom
Investigational Site Number : 8260001
Newcastle upon Tyne, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.